Distinguished in Hairy Cell Leukemia (HCL)

Achille Ambrosetti

Verona, IT 
Distinguished in Hairy Cell Leukemia (HCL)
Verona, IT 
OverviewLocationsClinical Research

Overview

Achille Ambrosetti practices in Verona, Italy. Mr. Ambrosetti is rated as a Distinguished expert by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Hairy Cell Leukemia (HCL), Leukemia, Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), and Bone Marrow Transplant.

His clinical research consists of co-authoring 34 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Hairy Cell Leukemia (HCL).

Gender
Male

Locations

Verona, Italy
Other Locations
Trieste, Italy
A.O. S. Giovanni Battista Molinette
Turin, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An International Phase II Trial Assessing Tolerability and Efficacy of Sequential Methotrexate-Aracytin-based Combination and R-ICE Combination, Followed by HD Chemotherapy Supported by ASCT, in Patients With Systemic B-cell Lymphoma With CNS Involvement at Diagnosis or Relapse (MARIETTA Regimen)
An International Phase II Trial Assessing Tolerability and Efficacy of Sequential Methotrexate-Aracytin-based Combination and R-ICE Combination, Followed by HD Chemotherapy Supported by ASCT, in Patients With Systemic B-cell Lymphoma With CNS Involvement at Diagnosis or Relapse (MARIETTA Regimen)
Enrollment Status: Completed
Publish Date: July 08, 2025
Intervention Type: Drug, Radiation
Study Drugs: Methotrexate, Rituximab, Cytarabine, Thiotepa, Liposomal Cytarabine, Etoposide, Ifosfamide, Carmustine
Study Phase: Phase 2
A Phase 2 Multicenter Study to Assess the Activity and the Safety of Front-line Ibrutinib Plus Rituximab (IR) in Unfit Patients With Chronic Lymphocytic Leukemia (CLL).
A Phase 2 Multicenter Study to Assess the Activity and the Safety of Front-line Ibrutinib Plus Rituximab (IR) in Unfit Patients With Chronic Lymphocytic Leukemia (CLL).
Enrollment Status: Completed
Publish Date: January 16, 2025
Intervention Type: Drug
Study Drugs: Ibrutinib, Rituximab
Study Phase: Phase 2
View 1 Less Clinical Trial

34 Total Publications

Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.
Journal: The New England journal of medicine
Published: May 12, 2021

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ambrosetti's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile